| Literature DB >> 34524621 |
J van Ramshorst1, M Duffels1, S P M de Boer1, A Bos-Schaap1, O Drexhage1, S Walburg2, J de Beij2, D van der Stoop1, V A W M Umans3.
Abstract
BACKGROUND: Healthcare expenditure in the Netherlands is increasing at such a rate that currently 1 in 7 employees are working in healthcare/curative care. Future increases in healthcare spending will be restricted, given that 10% of the country's gross domestic product is spent on healthcare and the fact that there is a workforce shortage. Dutch healthcare consists of a curative sector (mostly hospitals) and nursing care at home. The two entities have separate national budgets (€25 bn + €20 bn respectively) AIM: In a proof of concept, we explored a new hospital-at-home model combining hospital cure and nursing home care budgets. This study tests the feasibility of (1) providing hospital care at home, (2) combining financial budgets, (3) increasing workforces by combining teams and (4) improving perspectives and increasing patient and staff satisfaction.Entities:
Keywords: Antibiotic treatment; Endocarditis; Heart failure; Hospital at home
Year: 2021 PMID: 34524621 PMCID: PMC9123121 DOI: 10.1007/s12471-021-01614-2
Source DB: PubMed Journal: Neth Heart J ISSN: 1568-5888 Impact factor: 2.854
Fig. 1Organisational hospital-at-home model of the Noordwest Ziekenhuisgroep and Omring. On the left, the Noordwest activities and devices are depicted; on the right are those of Omring. Noordwest develops home-to-hospital protocols with mobile laboratory services and hospital-to-home protocols with Omring. Omring provides care at home with technical care nurses and nurse practitioners
Baseline characteristics of endocarditis-at-home patients
| Mean age (years) | 70 ± 10 |
|---|---|
| Female sex (%) | 32 |
| 26 | |
| HACEK | 1 |
| | 8 |
| Negative culture | 3 |
| Others | 3 |
| C-reactive protein (mg/l) | 103 |
| Creatinine (µmol/l) | 116 |
| Haemoglobulin (mmol/l) | 7.3 |
| Leucocytes (×10−9/l) | 11.2 |
| Cardiac valve | 8 |
| Aortic prosthesis | 1 |
| Pacemaker/ICD | 7 |
| Non-cardiac | 2 |
| Native valve | 18 |
| Prosthetic valve | 15 |
| Aortic prosthesis | 1 |
| Pacemaker/ICD | 6 |
| Other cardiac locationa | 1 |
ICD implantable cardioverter-defibrillator
aMyoma
Fig. 2C‑reactive protein (CRP) levels during admission and treatment at home. CRP levels of all endocarditis-at-home patients since hospital admission. Time = 0 Admission to the virtual ward for intravenous antibiotic treatment ‘endocarditis at home’
Baseline characteristics of heart-failure-at-home patients
| Mean age (years) | 76 |
|---|---|
| Female sex (%) | 8 |
| Hypertension | 9 |
| Diabetes | 3 |
| Previous MI | 6 |
| Previous CABG/PCI | 13 |
| Atrial fibrillation | 9 |
| HFpEF | 8 |
| HFmrEF | 4 |
| HFrEF | 4 |
| Pacemaker | 0 |
| ICD | 1 |
MI myocardial infarction, CABG coronary artery bypass grafting, PCI percutaneous coronary intervention, HFpEF heart failure with preserved ejection fraction, HFmrEF heart failure with mildly reduced ejection fraction, HFrEF heart failure with reduced ejection fraction, ICD implantable cardioverter-defibrillator
Biomarkers during heart-failure-at-home (H@H) therapy
| Admission | H@H start | H@H end | |
|---|---|---|---|
| Weight (kg) | 89.0 ± 18.2 | 87.8 ± 17.5 | 81.5 ± 17.0 |
| eGFR (ml/min) | 59 ± 21 | 59 ± 19 | 51 ± 21 |
| Urea (mmol/l) | 9.1 ± 3.7 | 10.2 ± 5.6 | 11.9 ± 4.4 |
| Sodium (mmol/l) | 137 ± 5 | 138 ± 6 | 137 ± 4 |
| Potassium (mmol/l) | 4.1 ± 0.6 | 4.0 ± 0.6 | 4.1 ± 0.4 |
eGFR estimated glomerular filtration rate